NCT03595020 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Takizawa R, Fukuda M, Kawasaki S, Kasai K, Mimura M, Pu S, Noda T, Niwa S, Okazaki Y; Joint Project for Psychiatric Application of Near-Infrared Spectroscopy (JPSY-NIRS) Group
Neuroimaging-aided differential diagnosis of the depressive state. Neuroimage. 2014 Jan 15;85 Pt 1:498-507. doi: 10.1016/j.neuroimage.2013.05.126. Epub 2013 Jun 10. Erratum in: Neuroimage. 2015 Apr 1;109:530.
Tsuchida A, Fellows LK
Are you upset? Distinct roles for orbitofrontal and lateral prefrontal cortex in detecting and distinguishing facial expressions of emotion. Cereb Cortex. 2012 Dec;22(12):2904-12. doi: 10.1093/cercor/bhr370. Epub 2012 Jan 5.
Zwick JC, Wolkenstein L
Facial emotion recognition, theory of mind and the role of facial mimicry in depression. J Affect Disord. 2017 Mar 1;210:90-99. doi: 10.1016/j.jad.2016.12.022. Epub 2016 Dec 19.

Probing Prefrontal Cortex Hemodynamic Alterations During Facial Emotion Recognition for Major Depression Disorder Through Functional Near-infrared Spectroscopy

Details for clinical trial NCT03595020

Clinical trial NCT03595020 - References